Verorab

BIOLOGICAL3 trials

Sponsors

Swiss Tropical & Public Health Institute, National Institute of Allergy and Infectious Diseases (NIAID), University of Oxford

Conditions

MalariaMeasles Infection

Phase 1

Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria Endemic Country

CompletedNCT05644067

Swiss Tropical & Public Health InstituteMalaria

Start: 2023-08-25End: 2024-04-02Updated: 2024-04-15

Unknown Phase

A study to find out if a new malaria vaccine regimen can protect against malaria in African adults.

Active, not recruitingPACTR201202000356208

University of OxfordMalaria

Start: 2012-02-01Target: 120Updated: 2026-08-03

Investigation of Immune Amnesia Following Measles Infection in Select African Regions

CompletedNCT06153979

National Institute of Allergy and Infectious Diseases (NIAID)Measles Infection

Start: 2024-01-16End: 2026-04-16Updated: 2026-05-12

Related Papers

Full-length merozoite surface protein 1 formulated with GLA-SE adjuvant in malaria pre-exposed adults: a randomised, controlled, double-blind, parallel-group, single-centre Phase Ib trial.

2025-10-25

Investigating immune amnesia after measles virus infection in two West African countries: A study protocol

PLoS ONE2025-06-26